These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36842301)

  • 1. Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy.
    Gouda MA; Subbiah V
    ESMO Open; 2023 Apr; 8(2):100788. PubMed ID: 36842301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers.
    Shan KS; Rehman TU; Ivanov S; Domingo G; Raez LE
    Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Development of BRAF plus MEK Inhibitor Combinations.
    Subbiah V; Baik C; Kirkwood JM
    Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors.
    Adashek JJ; Menta AK; Reddy NK; Desai AP; Roszik J; Subbiah V
    Mol Cancer Ther; 2022 Jun; 21(6):871-878. PubMed ID: 35413124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expert consensus on BRAF inhibitors in the treatment of malignant solid tumors (2024 edition)].
    ;
    Zhonghua Zhong Liu Za Zhi; 2024 Oct; 46(10):919-929. PubMed ID: 39414592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers.
    Rustgi N; Maria A; Toumbacaris N; Zhao H; Kargus K; Bryant M; Waksmundzki A; Aricescu I; Lefkowitz RA; Li BT; Chou J; Capanu M; de Stanchina E; Misale S; Shia J; Yaeger R
    Oncologist; 2024 Jan; 29(1):15-24. PubMed ID: 37616543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting
    Baik CS; Myall NJ; Wakelee HA
    Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "RB-reactivator screening" as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist).
    Sakai T
    Pharmacol Ther; 2022 Aug; 236():108234. PubMed ID: 35732246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.
    Riudavets M; Cascetta P; Planchard D
    Lung Cancer; 2022 Jul; 169():102-114. PubMed ID: 35696864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.
    Rajkumar S; Berry D; Heney KA; Strong C; Ramsay L; Lajoie M; Alkallas R; Nguyen TT; Thomson C; Ahanfeshar-Adams M; Dankner M; Petrella T; Rose AAN; Siegel PM; Watson IR
    Cell Rep; 2022 Apr; 39(1):110634. PubMed ID: 35385748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Therapy for Melanomas Without BRAF V600 Mutations.
    Menzer C; Hassel JC
    Curr Treat Options Oncol; 2022 Jun; 23(6):831-842. PubMed ID: 35380338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEK and RAF inhibitors for BRAF-mutated cancers.
    Belden S; Flaherty KT
    Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
    Boussemart L; Malka-Mahieu H; Girault I; Allard D; Hemmingsson O; Tomasic G; Thomas M; Basmadjian C; Ribeiro N; Thuaud F; Mateus C; Routier E; Kamsu-Kom N; Agoussi S; Eggermont AM; Désaubry L; Robert C; Vagner S
    Nature; 2014 Sep; 513(7516):105-9. PubMed ID: 25079330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
    Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
    Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A
    PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it.
    Tsamis I; Gomatou G; Chachali SP; Trontzas IP; Patriarcheas V; Panagiotou E; Kotteas E
    Clin Transl Oncol; 2023 Jan; 25(1):10-20. PubMed ID: 35729451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
    Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK
    PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Therapy for Melanoma.
    Wong DJ; Ribas A
    Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
    Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
    Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.
    Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H
    Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.